^
    Back
    Association details:
    Biomarker:MYCN expression
    Cancer:Non Small Cell Lung Cancer
    Drug:MRT-2359 (GSPT1 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Monte Rosa Therap Press Release
    Title:

    Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

    Published date:
    01/09/2023
    Excerpt:
    MRT-2359 received Fast Track designation from the FDA for the treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expression.